Vital Therapies (VTL) Shares Gap Down to $0.30

Vital Therapies Inc (NASDAQ:VTL)’s share price gapped down prior to trading on Tuesday . The stock had previously closed at $0.28, but opened at $0.30. Vital Therapies shares last traded at $0.31, with a volume of 8685498 shares changing hands.

VTL has been the subject of several research reports. William Blair downgraded Vital Therapies from an “outperform” rating to a “market perform” rating in a research report on Wednesday, September 12th. ValuEngine downgraded Vital Therapies from a “buy” rating to a “hold” rating in a research report on Wednesday, September 12th. Cantor Fitzgerald downgraded Vital Therapies from an “overweight” rating to a “neutral” rating in a research report on Wednesday, September 12th. BidaskClub downgraded Vital Therapies from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 16th. Finally, Raymond James downgraded Vital Therapies from an “outperform” rating to a “market perform” rating and set a $6.00 target price for the company. in a research report on Wednesday, September 12th. Seven investment analysts have rated the stock with a hold rating, The stock presently has an average rating of “Hold” and a consensus price target of $12.00.

The stock has a market cap of $11.67 million, a price-to-earnings ratio of -0.24 and a beta of 4.29.

Vital Therapies (NASDAQ:VTL) last released its earnings results on Tuesday, August 7th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.33) by $0.03. As a group, analysts anticipate that Vital Therapies Inc will post -1.11 EPS for the current fiscal year.

In other news, Director Muneer A. Satter sold 11,382,277 shares of Vital Therapies stock in a transaction dated Monday, September 17th. The stock was sold at an average price of $0.36, for a total value of $4,097,619.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Muneer A. Satter sold 447,500 shares of Vital Therapies stock in a transaction dated Friday, September 14th. The shares were sold at an average price of $0.36, for a total value of $161,100.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 11,929,271 shares of company stock valued at $4,292,912. 33.90% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in VTL. Northern Trust Corp boosted its stake in shares of Vital Therapies by 12.0% in the 1st quarter. Northern Trust Corp now owns 83,688 shares of the company’s stock valued at $569,000 after buying an additional 8,993 shares during the period. Citigroup Inc. boosted its stake in shares of Vital Therapies by 1,093.5% in the 1st quarter. Citigroup Inc. now owns 15,909 shares of the company’s stock valued at $108,000 after buying an additional 14,576 shares during the period. Element Capital Management LLC purchased a new position in shares of Vital Therapies in the 1st quarter valued at about $209,000. Millennium Management LLC boosted its stake in shares of Vital Therapies by 65.6% in the 1st quarter. Millennium Management LLC now owns 414,540 shares of the company’s stock valued at $2,819,000 after buying an additional 164,175 shares during the period. Finally, TD Asset Management Inc. boosted its stake in shares of Vital Therapies by 50.2% in the 2nd quarter. TD Asset Management Inc. now owns 36,344 shares of the company’s stock valued at $249,000 after buying an additional 12,144 shares during the period. Institutional investors and hedge funds own 32.62% of the company’s stock.

Vital Therapies Company Profile (NASDAQ:VTL)

Vital Therapies, Inc, a biotherapeutic company, focuses on developing and commercializing a cell-based therapy for the treatment of acute forms of liver failure in the United States. Its product candidate is the ELAD system, an extracorporeal human allogeneic cellular liver therapy that is in Phase III clinical trials helps in enhancing the rates of survival in patients with acute forms of liver failure.

Further Reading: What is the Dow Jones Industrial Average (DJIA)?

Receive News & Ratings for Vital Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply